Differential target multiplexed SCS (DTM SCS): a rational hypothesis

Area of Science:

• Neuroscience
• Biomedical Engineering
• Pain Management

Background:

• Spinal cord stimulation (SCS) therapy initially focused on paresthesia for chronic low back pain.
• Newer SCS modalities aim for long-term pain relief and reduced side effects.
• Emerging evidence suggests SCS modulates pain via Aβ-fibers and glial cell interactions.

Purpose of the Study:

• To highlight the rationale and development of Differential Target Multiplexed (DTM) SCS.
• To provide an overview of DTM SCS clinical applications.
• To review key outcomes of DTM SCS studies in chronic low back pain.

Main Methods:

• Differential Target Multiplexed (DTM) programming uses synchronous, multiplexed signals at varying rates and amplitudes.
• Preclinical studies in animal models demonstrated DTM SCS can revert spinal cord neurons and glia to a non-injured state.
• Review of randomized clinical trials (RCTs) comparing DTM SCS to other SCS treatments for chronic low back pain.

Main Results:

• DTM SCS demonstrated promise in preclinical transcriptomics and proteomics studies.
• Clinical studies and RCTs indicate DTM SCS may enhance outcomes for chronic low back pain patients.
• The development involved preclinical research, feasibility studies, and confirmatory RCTs.

Conclusions:

• DTM SCS represents an advancement in spinal cord stimulation therapy.
• The therapy is supported by preclinical findings and clinical trial evidence.
• DTM SCS shows potential for improved management of chronic low back pain.